Published in Clin Pharmacol Ther on January 01, 2004
Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol (2010) 1.20
Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins (Basel) (2010) 0.89
Effect of Repeated Wuniu Early Tea Administration on the CYP450 Activity Using a Cocktail Method. Indian J Pharm Sci (2013) 0.87
Clinical pharmacology in old persons. Scientifica (Cairo) (2012) 0.85
Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening. J Food Sci Technol (2014) 0.79
Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: Protective effect against environmental carcinogens? Clin Pharmacol Ther (2005) 0.78
Elevated international normalized ratio with the consumption of grapefruit and use of warfarin. SAGE Open Med Case Rep (2013) 0.75
Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA (2002) 5.80
Dietary supplement use in the United States, 2003-2006. J Nutr (2010) 4.72
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med (2003) 2.96
Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother (2009) 2.34
Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm (2004) 2.26
Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med (2002) 2.06
Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl (2012) 2.01
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. Health Serv Res (2005) 1.91
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
The caffeine contents of dietary supplements commonly purchased in the US: analysis of 53 products with caffeine-containing ingredients. Anal Bioanal Chem (2007) 1.86
Correlates of health literacy in patients with chronic heart failure. Gerontologist (2006) 1.75
NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. J Nutr (2010) 1.74
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis (2012) 1.63
Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy (2006) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Measuring vitamins and minerals in dietary supplements for nutrition studies in the USA. Anal Bioanal Chem (2007) 1.57
Comparison of quality of life measures in heart failure. Nurs Res (2003) 1.54
Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations. J Gen Intern Med (2004) 1.53
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer (2014) 1.51
Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis (2002) 1.50
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Biomarkers of vitamin B-12 status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
Biomarkers of folate status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther (2003) 1.42
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab (2013) 1.39
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Merck Sharp and Dohme versus Laporte. Lancet (2004) 1.37
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J (2006) 1.36
Cognition and health literacy in patients with hypertension. J Gen Intern Med (2008) 1.35
GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States. Am J Clin Nutr (2010) 1.32
Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J (2011) 1.30
Discriminant properties of commonly used quality of life measures in heart failure. Qual Life Res (2002) 1.30
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Dietary supplement ingredient database (DSID): Preliminary USDA studies on the composition of adult multivitamin/mineral supplements. J Food Compost Anal (2008) 1.28
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
The status of paediatric medicines initiatives around the world--What has happened and what has not? Eur J Clin Pharmacol (2011) 1.26
Development and certification of a standard reference material for vitamin D metabolites in human serum. Anal Chem (2011) 1.26
Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26
Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol (2010) 1.24
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther (2003) 1.22
Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med (2005) 1.19
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) (2005) 1.18
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18
Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther (2005) 1.16
Overview of a roundtable on NHANES monitoring of biomarkers of folate and vitamin B-12 status: measurement procedure issues. Am J Clin Nutr (2011) 1.16
Development of the analytical methods and reference materials program for dietary supplements at the National Institutes of Health. J AOAC Int (2004) 1.14
Cytokines and toxicity in acetaminophen overdose. J Clin Pharmacol (2005) 1.13
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13
Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13
Relationship of age and sex to health-related quality of life in patients with heart failure. Am J Crit Care (2004) 1.13
Computer access to research on dietary supplements: a database of federally funded dietary supplement research. J Nutr (2005) 1.12
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
The NIH analytical methods and reference materials program for dietary supplements. Anal Bioanal Chem (2007) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
Effect of health literacy on drug adherence in patients with heart failure. Pharmacotherapy (2012) 1.10
Prescription abandonment: another path to medication nonadherence. Ann Intern Med (2010) 1.10
Developmental pharmacokinetics. Handb Exp Pharmacol (2011) 1.09
Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08
Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care (2013) 1.08
Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07
Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Alcohol (2004) 1.07
Health care and medication costs and use among older adults with heart failure. Am J Med (2004) 1.06
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacotherapy (2006) 1.06
Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys. Am J Clin Nutr (2013) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04
Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother (2012) 1.04
Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy (2003) 1.03
Sustained neuronal activity generated by glial plasticity. J Neurosci (2011) 1.03
Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol (2004) 1.02
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J (2013) 1.02
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther (2006) 1.02
Summary of an NIH workshop to identify research needs to improve the monitoring of iodine status in the United States and to inform the DRI. J Nutr (2012) 1.02
Dietary supplements in weight reduction. J Am Diet Assoc (2005) 1.01
The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos (2002) 1.01
HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum (2006) 1.00
Mass media release of medical research results: an analysis of antihypertensive drug prescribing in the aftermath of the calcium channel blocker scare of March 1995. J Gen Intern Med (2003) 1.00
The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol (2003) 1.00
Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J (2008) 0.99
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99
Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol (2009) 0.99